CN113395977A - 百日咳加强疫苗 - Google Patents

百日咳加强疫苗 Download PDF

Info

Publication number
CN113395977A
CN113395977A CN201980090686.9A CN201980090686A CN113395977A CN 113395977 A CN113395977 A CN 113395977A CN 201980090686 A CN201980090686 A CN 201980090686A CN 113395977 A CN113395977 A CN 113395977A
Authority
CN
China
Prior art keywords
amount
vaccine
present
booster
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980090686.9A
Other languages
English (en)
Chinese (zh)
Inventor
N·伯丁
M·欧克斯
M·加里诺
M·夏博-里乌
N·里韦诺
刘元庆
N·米斯特雷塔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Inc
Original Assignee
Sanofi Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Inc filed Critical Sanofi Pasteur Inc
Publication of CN113395977A publication Critical patent/CN113395977A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CN201980090686.9A 2018-12-05 2019-11-29 百日咳加强疫苗 Pending CN113395977A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18306621.6 2018-12-05
EP18306621 2018-12-05
PCT/US2019/063840 WO2020117618A1 (en) 2018-12-05 2019-11-29 Pertussis booster vaccine

Publications (1)

Publication Number Publication Date
CN113395977A true CN113395977A (zh) 2021-09-14

Family

ID=65628487

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980090686.9A Pending CN113395977A (zh) 2018-12-05 2019-11-29 百日咳加强疫苗

Country Status (6)

Country Link
US (1) US20220054615A1 (https=)
EP (1) EP3890770A4 (https=)
JP (2) JP7605739B2 (https=)
CN (1) CN113395977A (https=)
TW (1) TWI877126B (https=)
WO (1) WO2020117618A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115554395A (zh) * 2022-10-12 2023-01-03 长春百克生物科技股份公司 一种百白破复合佐剂联合疫苗

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230072809A1 (en) * 2020-03-09 2023-03-09 Dynavax Technologies Corporation Active booster immunization against tetanus, diphtheria and pertussis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX372965B (es) * 2012-03-08 2020-04-01 Glaxosmithkline Biologicals Sa Formulaciones adyuvadas de vacunas de difteria, tetanos y tos ferina (dtp) de refuerzo.
CN104159603A (zh) * 2012-03-08 2014-11-19 诺华股份有限公司 带有tlr4激动剂的联合疫苗
WO2014024026A1 (en) * 2012-08-06 2014-02-13 Glaxosmithkline Biologicals S.A. Method for eliciting in infants an immune response against rsv and b. pertussis
US9526776B2 (en) * 2012-09-06 2016-12-27 Glaxosmithkline Biologicals Sa Combination vaccines with serogroup B meningococcus and D/T/P
US20180296663A1 (en) * 2015-06-17 2018-10-18 Curevac Ag Vaccine composition

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115554395A (zh) * 2022-10-12 2023-01-03 长春百克生物科技股份公司 一种百白破复合佐剂联合疫苗
WO2024078170A1 (zh) * 2022-10-12 2024-04-18 长春百克生物科技股份公司 一种百白破复合佐剂联合疫苗

Also Published As

Publication number Publication date
TWI877126B (zh) 2025-03-21
WO2020117618A1 (en) 2020-06-11
EP3890770A4 (en) 2022-09-28
EP3890770A1 (en) 2021-10-13
JP7605739B2 (ja) 2024-12-24
TW202038991A (zh) 2020-11-01
US20220054615A1 (en) 2022-02-24
JP2022511511A (ja) 2022-01-31
JP2024156862A (ja) 2024-11-06

Similar Documents

Publication Publication Date Title
Duan et al. Review of newly identified functions associated with the heat-labile toxin of enterotoxigenic Escherichia coli
Brennan et al. Pseudomonas aeruginosa outer-membrane protein F epitopes are highly immunogenic in mice when expressed on a plant virus
JP5931724B2 (ja) ＳｔｒｅｐｔｏｃｏｃｃｕｓＰｎｅｕｍｏｎｉａｅに対するワクチンおよび組成物
US12440547B2 (en) Live salmonella typhi vectors engineered to express heterologous outer membrane protein antigens and methods of use thereof
Dull et al. Meningococcal vaccine development–from glycoconjugates against MenACWY to proteins against MenB–potential for broad protection against meningococcal disease
CA2903937C (en) Acellular pertussis vaccine
JP2024156862A (ja) 百日咳ブースターワクチン
KR20180099912A (ko) 나이세리아 메닌지티디스 조성물 및 그의 방법
WO2021158440A1 (en) Immunogenic compositions to treat and prevent microbial infections
Auderset et al. Reactivating immunity primed by acellular pertussis vaccines in the absence of circulating antibodies: enhanced bacterial control by TLR9 rather than TLR4 agonist-including formulation
TW202245836A (zh) 重組ｂ型腦膜炎球菌疫苗
Grover et al. Porphyromonas gingivalis antigenic determinants-potential targets for the vaccine development against periodontitis
JP7650871B2 (ja) 免疫原性組成物
Sam et al. Diphtheria toxoid particles as Q fever vaccine
JP6401148B2 (ja) 抗原および抗原の組み合わせ
Hou et al. Chimeric hepatitis B virus core particles displaying Neisserial surface protein A confer protection against virulent Neisseria meningitidis serogroup B in BALB/c mice
US12403189B2 (en) Immunogenic antigens
CA3100212A1 (en) Streptococcal toxic shock syndrome
US20230104907A1 (en) Live salmonella typhi vectors engineered to express protein antigens and methods of use thereof
KR20200115522A (ko) IgE 매개된 알레르기성 질환의 치료를 위해 막-결합된 IgE를 표적화하는 펩타이드 면역원 및 이의 제형물
Yount Improved vaccines against Bordetella pathogens utilizing Th1/17-polarizing adjuvant BcfA and mucosal immunization strategies
WO2022160017A1 (en) Sars-cov-2 vaccine antigens
Ferreira et al. Su. 55. Cytotoxin Neutralization and Enzyme-Linked Immunosorbent Assays for Escherichia Coli Toxins
OA17719A (en) Acellular pertussis vaccine.
WO2016012951A1 (en) Immunogenic conjugate

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Country or region after: U.S.A.

Address after: Pennsylvania, USA

Applicant after: Sanofi Vaccines USA

Address before: Pennsylvania, USA

Applicant before: SANOFI PASTEUR, Inc.

Country or region before: U.S.A.